Skip to content
Home/Companies/MedTech/Xeltis
Xeltis

Xeltis

MedTech·NL·Active·9yr hold
Entry
2017
Hold
9yr
Status
Active

Who owns Xeltis?

Xeltis is currently owned by Ysios Capital Partners through Ysios BioFund II Innvierte (2016 vintage), since 2017.

Hand-verified · updated 2026-04-21

Ysios Capital Partners
Investor
Ysios Capital Partners
Ysios BioFund II Innvierte · 2016 · Life Sciences VC

Key facts

HQFrance
SectorMedTech
Websitexeltis.com

More from Ysios BioFund II Innvierte

Other portfolio companies in the same fund.

Anaconda Biomed
Anaconda Biomed
Active
MedTechES· 2017
Babyscripts
Babyscripts
Active
HealthTechUS· 2017
Prexton Therapeutics
Exited 2018
BiotechCH· 2017
to
Vivet Therapeutics
Vivet Therapeutics
Active
BiotechFR· 2017
AELIX Therapeutics
AELIX Therapeutics
Active
BiotechES· 2016
CorWave
CorWave
Active
MedTechFR· 2016

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Acufocus, Inc.
Exited 2023
The Carlyle GroupUS
to
Adicon Holdings Limited
Active
The Carlyle GroupUS
Aesynt
Exited 2016
Francisco PartnersUS
to
Alere Medical, Inc.
Active
TA AssociatesUS
Alma Lasers, Ltd.
Alma Lasers, Ltd.
Active
TA AssociatesIsrael
Amedes Group
Active
General AtlanticGermany
Track Xeltis

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Xeltis?

5 strategic and 115financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Xeltis.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue